

Margaret Bolce Brivanlou, PHD (Peg)

Partner

*Trial and Global Disputes / Intellectual
Property, Patent, Trademark and
Copyright Litigation*

New York: +1 212 556 2270
pbrivanlou@kslaw.com



Peg Brivanlou specializes in patent prosecution, client counseling, due diligence and patent litigation. As a Partner in our Intellectual Property, Patent, Trademark and Copyright Litigation practice, Peg represents clients in the biotechnology and pharmaceutical industries, and investment funds in a variety of intellectual property matters.

With a focus on biologics and small molecule therapeutics, Peg counsels clients regarding immunotherapeutics, cell-based assays and therapies, genomics, bioinformatics, vaccines and small molecule pharmaceuticals. She is experienced in developing patent portfolios, particularly relating to biologics, antibody therapeutics and diagnostics. She also conducts patent invalidity, freedom-to-operate analyses and pre-litigation investigations, including for pre-Hatch-Waxman litigation.

In addition, Peg represents clients on the intellectual property aspects of a wide range of transactions, from technology transfer and out-licensing to multi-million-dollar asset purchases and financings. She conducts due diligence, and negotiates licensing and purchase agreements as well as disclosure documents in connection with public and private financings.

Presenting to conferences and in-house counsel, Peg is a frequent speaker on a variety of patent issues.

Matters

Primary intellectual property counsel to **a private investment fund** in connection with significant royalty stream acquisitions and financings.

Represents **a private biotechnology company** in developing patent portfolio relating to immunotherapeutics.

Represents **a major pharmaceutical company** in patent prosecution and counseling relating to small molecule pharmaceuticals, including approved products and products in late stage clinical

trials, for cardiovascular indications.

Represents a **foreign pharmaceutical firm** in patent prosecution and counseling relating to RNAi therapeutics.

Represented a **major pharmaceutical company and private biotechnology companies** in administrative and court challenges against the USPTO relating to patent term adjustment calculations.

Credentials

EDUCATION

J.D., Harvard University, cum laude
Ph.D., University of California, Berkeley
A.B., Cornell University, magna cum laude

ADMISSIONS

U.S. Patent and Trademark Office
New York

ASSOCIATIONS

New York State Bar Association
New York Intellectual Property Law Association

LANGUAGES

French

Insights

ARTICLE

June 15, 2017 • Source: Law360
High Court's Superficial Analysis In Biosimilars Ruling

June 12, 2017 • Source: Intellectual Property Magazine
Clarity From Chaos

CLIENT ALERT

June 13, 2017
The Age of Competition

[VIEW ALL ON KSLAW.COM](http://www.kslaw.com)

Events

CONFERENCE

April 11, 2018
Crash Course on Biologics Litigation from a Regulatory and Patent Perspective Luncheon

September 7, 2017
Medical Device Summit 2017

WEBINAR

January 23, 2018
Crash Course on Biologics Litigation from a Regulatory and Patent Perspective

[VIEW ALL ON KSLAW.COM](#)

News

IN THE NEWS

February 27, 2019 • Source: WebMD

Peg Brivanlou discussed her pro bono efforts for a rare disease family foundation

RECOGNITION

October 4, 2019

LMG Life Sciences Recognizes King & Spalding With Multiple Rankings in its 2019 Guide

June 10, 2019

King & Spalding IP Practices and Individuals Recognized in the IAM Patent 1000 Guide

[VIEW ALL ON KSLAW.COM](#)